The ACURATE Prime Aortic Valve System, the most recent addition to Boston Scientific Corporation's transcatheter aortic valve replacement technology portfolio, has been granted the CE mark. The new ACURATE Prime system develops upon the clinical performance of the ACURATE neo2 platform, providing improvements such as an additional valve size to accommodate patients with larger anatomies. The ACURATE Prime valve system is intended to restore normal blood flow through a narrowed aortic valve in patients at low, intermediate, and high risk of severe aortic stenosis. The new system has expanded the scope of care for aortic valve disease by providing treatment for patients with aortic annulus diameters ranging from 20.5 to 29mm.
"We are thrilled to offer physicians a new valve with meaningful improvements for the treatment of an increasing number of patients with aortic valve disease," said Lance Bates, Senior Vice President and President of Interventional Cardiology Therapies at Boston Scientific. For over 45 years, Boston Scientific has been a global leader in medical technology, committed to the advancement of science by providing high-performance solutions that address unmet patient requirements and contribute to the reduction of healthcare costs on a global scale.
